November 23, 2019 - SCN2A Australia

Categories

Webinar

Developing Treatment for SCN2A

Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.

Sign up to the newsletter for updates.

SCN2A Asia PacificFollow

Working towards a cure for SCN2A, Raising Awareness and SCN2A Organisation for SCN2A families in Australia & across South East Asia.

Retweet on Twitter SCN2A Asia Pacific Retweeted

pedneurojournal @pedneurojournal·

6 Jan

Does genetic testing change #epilepsy treatment?

Genetic cause in 25% infant/ped onset epilepsy
- Impact treatment in 45%:
- 36% antiseizure med choice
- 7% vitamin/metabolic tx
- 3% pathway-driven off-label use med
- 10% gene-specific clinical trials
https://bit.ly/3VTqJ10

Reply on Twitter 1611392247425114112 Retweet on Twitter 161139224742511411226 Like on Twitter 161139224742511411264 Twitter 1611392247425114112

SCN2A Asia Pacific @SCN2AAustralia·

22 Dec

In 2022, SCN2A Asia Pacific has been able to increase our impact due to the support of our partners and sponsors.

We would like to thank @epilepsy_fdn for their support of our mission and for helping us with our activities in 2022. #SCN2A

Reply on Twitter 1606039569933008899 Retweet on Twitter 1606039569933008899 Like on Twitter 1606039569933008899 Twitter 1606039569933008899

SCN2A Asia Pacific @SCN2AAustralia·

22 Dec

In 2022, SCN2A Asia Pacific has been able to increase our impact due to the support of our partners and sponsors.

We would like to thank @OxPharmaGenesis for their support of our mission and for helping us with our activities in 2022. #SCN2A

Reply on Twitter 1606037590746230784 Retweet on Twitter 1606037590746230784 Like on Twitter 16060375907462307841 Twitter 1606037590746230784